Sword Bio and Alturas Analytics today announced a strategic collaboration designed to provide biotechnology and pharmaceutical companies with coordinated access to complementary bioanalytical capabilities across large- and small-molecule drug development.
MOSCOW, Idaho, Oct. 26, 2026 /PRNewswire-PRWeb/ -- Sword Bio and Alturas Analytics today announced a strategic collaboration designed to provide biotechnology and pharmaceutical companies with coordinated access to complementary bioanalytical capabilities across large- and small-molecule drug development.
The collaboration brings together Sword Bio's expertise in ligand-binding assays, including pharmacokinetic (PK), immunogenicity and biomarker applications, with Alturas Analytics' expertise in LC-MS/MS bioanalysis supporting preclinical and clinical research. Together, the organizations will provide sponsors with access to specialized scientific teams and technologies through a more coordinated framework, helping simplify complex bioanalytical programs while maintaining responsiveness, flexibility and direct scientific communication associated with specialized CROs.
The relationship is particularly well suited for programs that span both large- and small-molecule bioanalysis, including antibody-drug conjugates (ADCs). These complex therapeutics can require multiple analytical strategies and technologies to characterize the antibody, payload and immune response. By coordinating their complementary areas of expertise, Sword Bio and Alturas Analytics can help sponsors manage these multifaceted bioanalytical needs with greater continuity and streamlined communication.
"Our clients are developing increasingly complex therapeutics that require expertise across multiple bioanalytical platforms. This collaboration with Alturas allows us to bring together complementary scientific capabilities while giving sponsors the responsive, highly collaborative experience they expect from a specialized CRO. For programs such as ADCs, that means a more coordinated approach to bioanalysis, streamlined communication, and a team focused on moving the program forward efficiently."
— Jim McNally, Ph.D., Chief Scientific Officer, Sword Bio
Sword Bio provides bioanalytical support for preclinical and clinical development, with expertise in assay development, validation and sample analysis under regulated and non-regulated conditions. Its scientists support PK, immunogenicity and biomarker assays throughout drug development, providing sponsors with the scientific expertise, data integrity and regulatory focus required to advance their programs.
Alturas Analytics is a regulated bioanalytical CRO specializing in LC-MS/MS solutions for preclinical and clinical research. Alturas provides high-quality bioanalytical data to support drug development programs from early-stage research through clinical development, including studies that contribute to regulatory submissions. In addition to providing PK support services to pharmaceutical and biotechnology companies worldwide, Alturas maintains an active research program focused on applying emerging technologies and analytical approaches to advance bioanalytical science.
Since 2000, Alturas has built its business around long-term client relationships, combining deep scientific expertise with high-quality bioanalytical results and timely execution. The two organizations share a commitment to scientific collaboration, responsiveness and direct access to experienced scientists, creating a strong foundation for a mutually beneficial partnership.
"Our organizations share a commitment to rigorous science, responsive communication and building long-term relationships with our clients. By combining Alturas' depth of expertise in mass spectrometry-based bioanalysis with Sword Bio's expertise in ligand-binding and immunogenicity assays, we can provide sponsors with a more coordinated approach to increasingly complex development programs. The goal is to make it easier for our clients to access the right scientific expertise while maintaining the quality, communication and accountability they expect from both organizations."
— Jennifer Zimmer, Ph.D., Chief Operating Officer, Alturas Analytics
Specialized Expertise, Coordinated for Complex Programs:
Through the collaboration, Sword Bio and Alturas Analytics can provide sponsors with a coordinated approach to studies requiring multiple bioanalytical disciplines. The relationship is designed to reduce the operational burden associated with independently managing multiple specialty providers through centralized communication, scientific coordination and streamlined project execution.
This model combines the depth of specialized functional expertise with a more integrated sponsor experience. Both organizations remain focused on their respective areas of scientific strength while working collaboratively on program strategy, execution and communication when studies require capabilities from both teams.
For ADC programs in particular, the complementary capabilities create an opportunity to coordinate bioanalytical strategies across multiple components of these complex therapeutics. Alturas Analytics routinely provides mass spectrometry-based bioanalytical support and noncompartmental analysis (NCA), while Sword Bio provides ligand-binding and immunogenicity expertise, including anti-drug antibody (ADA) assessment. Together, these capabilities can provide sponsors with a more coordinated approach to generating and interpreting bioanalytical data across complex development programs. Beyond ADCs, the collaboration seamlessly supports biotechnology and pharmaceutical sponsors whose development programs require a combination of large- and small-molecule bioanalytical expertise. By bringing the appropriate scientific teams together within a coordinated framework, the organizations aim to make complex studies easier for sponsors to manage without sacrificing specialized expertise or personalized service.
The companies will remain independent organizations while collaborating on appropriate client programs. Each organization will continue to provide its existing services independently in addition to participating in jointly supported programs.
About Sword Bio:
Sword Bio is a bioanalytical contract research organization that partners with biotechnology and pharmaceutical companies to deliver data essential to their drug development needs. Sword Bio's team of experienced scientists provides assay development, validation and sample analysis under regulated and non-regulated conditions, supporting PK, immunogenicity and biomarker assays for preclinical and clinical studies.
Sword Bio combines scientific expertise with a highly collaborative approach focused on high-quality science, data integrity, regulatory compliance, responsiveness and on-time execution. By starting projects quickly and maintaining close communication throughout each engagement, Sword Bio helps clients efficiently advance their drug development programs. For more information, visit www.swordbio.com.
About Alturas Analytics:
Alturas Analytics is an independently owned, regulated bioanalytical CRO specializing in LC-MS/MS solutions focused on drug development. Since 2000, Alturas has provided bioanalytical services for preclinical and clinical research, generating high-quality data to support drug development programs from early-stage research through clinical development and regulatory submissions.
In addition to providing PK support services, including noncompartmental analysis (NCA), to pharmaceutical and biotechnology companies worldwide, Alturas maintains an intensive research effort focused on applying new technologies and analytical approaches to advance bioanalytical science. The company's success is built on developing long-term client relationships by combining scientific expertise with high-quality bioanalytical results, responsive service and timely execution. For more information, visit www.alturasanalytics.com.
Media Contact
ERIK BURNS, Alturas Analytics, 1 6126952601, [email protected], https://alturasanalytics.com/
SOURCE Alturas Analytics
Share this article